Bimekizumab Efficacy through Year 1 in Patients with Moderate to Severe Plaque Psoriasis Who Had Not Achieved a PASI 90 Response by Week 16: A Pooled Analysis from Four Phase 3/3B Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 2, p. s369, 2024. DOI: 10.25251/skin.8.supp.369. Disponível em: https://skin.dermsquared.com/skin/article/view/2701. Acesso em: 17 apr. 2026.